DURHAM, N.C., Jan. 17, 2025 (GLOBE NEWSWIRE) — Scorpius Holdings, Inc (NYSE American: SCPX) (Scorpius or the Firm), an built-in contract improvement and manufacturing group (CDMO), at present introduced that the Firm’s deliberate 1-for-20 reverse inventory break up (the Reverse Inventory Cut up) of its frequent inventory (the Frequent Inventory) that was introduced yesterday, won’t be effectuated.
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an built-in contract improvement and manufacturing group (CDMO) centered on quickly advancing biologic applications to the clinic and past. Scorpius gives a broad array of analytical testing, course of improvement, and manufacturing providers to pharmaceutical and biotech corporations at its state-of-the-art amenities in San Antonio, TX. With an skilled staff and new, purpose-built U.S. amenities, Scorpius is devoted to clear collaboration and versatile, high-quality biologics biomanufacturing. For extra info, please go to www.scorpiusbiologics.com.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
ir@scorpiusbiologics.com
Supply: Scorpius Holdings, Inc.
